Drug Resistance in Epilepsy: Lessons from Oncology

Chair's Introduction (V. Ling).

The problem of the drug-resistant epilepsies (J. W. Sander).

Drug resistance molecules: lessons from oncology (George L.Scheffer and Rik J. Scheper).

Drug resistance in epilepsy: the role of the blood-brain barrier(N. Joan Abbott, et al.).

P glycoprotein and the mechanism of multidrug resistance (A.Varadi, et al).

Drug resistance caused by multidrug resistance-associated proteins(J. Wijnholds).

Reversal of multidrug resistance: lessons from clinical oncology(S. E. Bates, et al.).

Clinical development of P glycoprotein modulators in oncology (A.Oza).

Gene expression profiling of epothilone A-resistant cells (P.Atadja, et al.).

Imaging of P glycoprotein function in vivo with PET (N. H.Hendrikse and W. Vaalburg).

Animal models of drug-resistant epilepsy (W. Loscher).

Drug resistance in epilepsy: human epilepsy (S. M. Sisodiya, etal).

Cellular mechanisms of pharmacoresistance in slices from epilepsysurgery (R. A. Deisz).

Functional polymorphisms of the human multidrug resistance (MDR1)gene: correlation with P glycoprotein expression and activity invivo (U. Brinkmann).

OC144-093, a novel P glycoprotein inhibitor for the enhancement ofanti-epileptic therapy (M. J. Newman, et al.).

Closing remarks (V. Ling).

Index of contributors.

Subject Index.